The use of the naturally occurring cannabinoid CBD (cannabidiol) possesses no likely abuse potential and therefore should not be subject to international drug scheduling restrictions, according to recommendations finalized today by the World Health Organization’s Expert Committee on Drug Dependence.
The use of the naturally occurring cannabinoid CBD is safe, well tolerated, and is not associated with any significant adverse public health effects, according to the findings of a preliminary report compiled by the World Health Organization’s Expert Committee on Drug Dependence. The agency is in the process of considering whether to place CBD within the agency’s international drug scheduling code.
The US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … under medical supervision.”
Some republican lawmakers in Wisconsin are reconsidering their position on marijuana reforms during the 2017 legislative session.
Members of Congress this week heard testimony on the state of marijuana research, and leading members of the US Senate introduced legislation to potentially reclassify CBD. A medical marijuana initiative in Montana qualified for the November ballot and Governors in three states signed marijuana related bills into law. Click here to get this week’s latest marijuana news and to find out how you can #TakeAction.